Download e-book for iPad: Cumulative Subject Index Volumes 50-72 by George F. Vande Woude, George Klein

By George F. Vande Woude, George Klein

ISBN-10: 0120066734

ISBN-13: 9780120066735

Educational Press proudly offers this Cumulative topic Index protecting Volumes 50-72 of Advances in melanoma study. in a single accomplished resource, the reader can locate references to precise articles on themes corresponding to breast melanoma, prostate melanoma, Kaposi's sarcoma, Burkitt's lymphoma, leukemias, oncogenes, transcription elements, tumor genetics, p53, T-cell receptors, and drug resistance. This cumulative index will serve not just as an entire evaluate of the main issues released in Advances in melanoma examine, but additionally as a trademark of the growth made in melanoma examine during the last ten years.

Show description

Read or Download Cumulative Subject Index Volumes 50-72 PDF

Best science (general) books

Download e-book for iPad: Advances In Atomic, Molecular, and Optical Physics, Vol. 30 by David Bates (ed.), Benjamin Bederson (ed.)

This sequence, proven in 1965, addresses fresh advancements within the normal zone of atomic, molecular, and optical physics. the sector is in a kingdom of speedy progress, as new experimental and theoretical concepts are delivered to endure on many aged and new difficulties. Such difficulties diversity from experiences of the basic homes of radiation and subject, via stories of hitherto inaccesible states of "ordinary" and unique atoms and molecules, the keep watch over of atoms and molecules via gentle, the behaviour of atoms and molecules in excessive radiation fields, the specific constitution of such platforms, together with advanced molecules and molecular clusters, and quite a lot of interplay phenomena between atoms, molecules, and their constituent elements and fields.

Download PDF by Steve L. Taylor: Advances in Food and Nutrition Research, Vol. 42

Advances in nutrients and food examine acknowledges the critical courting among the foodstuff and dietary sciences and brings jointly awesome and complete experiences that spotlight this courting. Contributions aspect the medical advancements within the extensive components encompassed via the fields of nutrients technology and nutrients and are meant to make sure that nutrition scientists in educational and in addition to expert nutritionists and dieticians are saved expert pertaining to rising learn and advancements in those vital disciplines.

Download e-book for iPad: Advances in Multimedia Modeling: 15th International by Benoit Huet, Alan F. Smeaton, Ketan Mayer-Patel, Yannis

This publication constitutes the refereed court cases of the fifteenth overseas Multimedia Modeling convention, MMM 2009, held in Sophia-Antipolis, France, in January 2009. The 26 revised complete papers and 20 revised poster papers provided including 2 invited talks have been conscientiously reviewed and chosen from a hundred thirty five submissions.

Prof. Vladimir V. Anisimov (auth.), Alessandra Giovagnoli,'s mODa 9 – Advances in Model-Oriented Design and Analysis: PDF

The amount includes the court cases of the ninth Workshop on Model-Oriented layout and research. It bargains top and pioneering paintings on optimum experimental designs, either from a theoretical perspective and in recognize of actual purposes. Scientists from japanese and Western Europe, the U.S., Asia and Africa, are participants to this quantity.

Extra info for Cumulative Subject Index Volumes 50-72

Sample text

5-56,60,62 Amino acid structure, VEGF, 67:284-286 6-Aminocaproic acid, plasminogen binding, 69:102 6-Aminolevulinic synthetase gene, c-erbA and, 59:104 Ammonium 2 1 tungsto-9-antimoniate, AIDS and, 51:347,356 Ammonium chloride, lysosomes and, 60: 284-285 Amphiregulin, transforming growth factor-a and, 58:28,37 Amphoterin, plasminogen binding, 69: 106 Amphotropic viruses development, from MuLV cancer resistant mice, 65: 177 effect of F v - 4 on, 65:190 Amplification, see Gene amplification Amplified DNA, evolution, 61:108-110 Amyloidosis, cutaneous lichen, with MEN IIA, 70:186-187 Anaphylaxis with desensitization reaction, Zilber and, 59:26-27 Anaplastic astrocytoma, oncogenesis of, 58: 124-125 8 Anatomy CpG islands in tumor suppressor genes, 72: 182-184 DNA methylation in higher-order eukaryotes, 72:147-150 Androgen receptor gene amplification in prostate cancer, 68: 247-248 mutations in prostate cancer metastasis, 68: 246 Androgens diet and, 51:63-64 endogenous growth inhibitors and, 57:436 mouse retrotransposons and, 56:231,240, 242 prostaticcancer and, 51:31-32 Anemia chromosome abnormalities and, 52:13 DHEA and, 51:418 protein tyrosine kinase GFRs and, 60: 52-53 refractory, see Refractory anemia Aneuploidy carcinogenesis and, role in cellular transformation, 65:2 1 chemical carcinogenesis and, 50:33 genomic instability and, 60:122,124, 135-136 p53 mutations and, 71:7-8 Angiogenesis in embryo chorioallantoic membrane, okadaic acid-induced, 61:164 FGF receptor multigene family and, 60: 2-3,35 fibroblast growth factors and, 59: 115-116,122,155 biological function, 59:140-142 tumors, 59:149,153-155 in human cancers, 67:266-267 and 1L-6 production, 66:ll inhibitors, 69:139-140,142 in vivo assays, 67:263-266 in Kaposi’s sarcoma, 53:83-84 normal cells, 69:135 occurrences, natural, 69:141 protein tyrosine kinase GFRs and, 6 0 5 0 regulation by VEGF-Flt receptors, 67: 28 1-282 role of SF, 67271-275 and scatter factor, 66:245 Subject Index separate from solid tumor development, 72: 18-19 therapeutic strategies using, 69160- 16 1 transforming growth factor-cu and, 58:47 tumor macrophage role, 6E269-270 PDGF role, 67:295-296 suppression, 67:309-310 tumor cells, 69:135-136,161-162 inducers, 69:142-149 inhibitor down-regulation, 69:149-156 mechanisms, 6 9 9 36- 137 phenotype, 69:139-141,156-159 subversion of normal physiological system, 69:141-142 Angiogenin, 69:144 Angioimmunoblastic lymphadenopathy, see Lymphadenopathy, angioimmunoblastic Angiolipoma, chromosomal aberrations, 69: 69-72 Angiopeptin, breast cancer therapy, 68:212 Angiostatin, 69:150,151 Angiotensin II,69:144 Animal models DNA methylation changes in cancer, 72: 175-1 76 lung carcinogenesis, p16 gene studies, 72: 162-163,187 Aniridia, Wilms’ tumor and, 59:47-50, 53-54,62 Ankyrin repeat domain, in IKB proteins, 66: 266-269 Antagonism, muscle cell regulation and, 58: 108-114 Antagonistic effects, cancer immunotherapy and, 59:262 Anthracyclins a-fetoprotein and, 56:280,287 lysosomes and, 60:284-285 multidrug resistance and, 52:170, 193 Antiandrogens, prostatic cancer and, 51:2 Antiangiogenic agents, 69160-161 Antibodies, see also Immunoglobulins; Monoclonal antibodies 4D5, HER-2/neu immunotherapy, 71:362 A .

5-56,60,62 Amino acid structure, VEGF, 67:284-286 6-Aminocaproic acid, plasminogen binding, 69:102 6-Aminolevulinic synthetase gene, c-erbA and, 59:104 Ammonium 2 1 tungsto-9-antimoniate, AIDS and, 51:347,356 Ammonium chloride, lysosomes and, 60: 284-285 Amphiregulin, transforming growth factor-a and, 58:28,37 Amphoterin, plasminogen binding, 69: 106 Amphotropic viruses development, from MuLV cancer resistant mice, 65: 177 effect of F v - 4 on, 65:190 Amplification, see Gene amplification Amplified DNA, evolution, 61:108-110 Amyloidosis, cutaneous lichen, with MEN IIA, 70:186-187 Anaphylaxis with desensitization reaction, Zilber and, 59:26-27 Anaplastic astrocytoma, oncogenesis of, 58: 124-125 8 Anatomy CpG islands in tumor suppressor genes, 72: 182-184 DNA methylation in higher-order eukaryotes, 72:147-150 Androgen receptor gene amplification in prostate cancer, 68: 247-248 mutations in prostate cancer metastasis, 68: 246 Androgens diet and, 51:63-64 endogenous growth inhibitors and, 57:436 mouse retrotransposons and, 56:231,240, 242 prostaticcancer and, 51:31-32 Anemia chromosome abnormalities and, 52:13 DHEA and, 51:418 protein tyrosine kinase GFRs and, 60: 52-53 refractory, see Refractory anemia Aneuploidy carcinogenesis and, role in cellular transformation, 65:2 1 chemical carcinogenesis and, 50:33 genomic instability and, 60:122,124, 135-136 p53 mutations and, 71:7-8 Angiogenesis in embryo chorioallantoic membrane, okadaic acid-induced, 61:164 FGF receptor multigene family and, 60: 2-3,35 fibroblast growth factors and, 59: 115-116,122,155 biological function, 59:140-142 tumors, 59:149,153-155 in human cancers, 67:266-267 and 1L-6 production, 66:ll inhibitors, 69:139-140,142 in vivo assays, 67:263-266 in Kaposi’s sarcoma, 53:83-84 normal cells, 69:135 occurrences, natural, 69:141 protein tyrosine kinase GFRs and, 6 0 5 0 regulation by VEGF-Flt receptors, 67: 28 1-282 role of SF, 67271-275 and scatter factor, 66:245 Subject Index separate from solid tumor development, 72: 18-19 therapeutic strategies using, 69160- 16 1 transforming growth factor-cu and, 58:47 tumor macrophage role, 6E269-270 PDGF role, 67:295-296 suppression, 67:309-310 tumor cells, 69:135-136,161-162 inducers, 69:142-149 inhibitor down-regulation, 69:149-156 mechanisms, 6 9 9 36- 137 phenotype, 69:139-141,156-159 subversion of normal physiological system, 69:141-142 Angiogenin, 69:144 Angioimmunoblastic lymphadenopathy, see Lymphadenopathy, angioimmunoblastic Angiolipoma, chromosomal aberrations, 69: 69-72 Angiopeptin, breast cancer therapy, 68:212 Angiostatin, 69:150,151 Angiotensin II,69:144 Animal models DNA methylation changes in cancer, 72: 175-1 76 lung carcinogenesis, p16 gene studies, 72: 162-163,187 Aniridia, Wilms’ tumor and, 59:47-50, 53-54,62 Ankyrin repeat domain, in IKB proteins, 66: 266-269 Antagonism, muscle cell regulation and, 58: 108-114 Antagonistic effects, cancer immunotherapy and, 59:262 Anthracyclins a-fetoprotein and, 56:280,287 lysosomes and, 60:284-285 multidrug resistance and, 52:170, 193 Antiandrogens, prostatic cancer and, 51:2 Antiangiogenic agents, 69160-161 Antibodies, see also Immunoglobulins; Monoclonal antibodies 4D5, HER-2/neu immunotherapy, 71:362 A .

5-56,60,62 Amino acid structure, VEGF, 67:284-286 6-Aminocaproic acid, plasminogen binding, 69:102 6-Aminolevulinic synthetase gene, c-erbA and, 59:104 Ammonium 2 1 tungsto-9-antimoniate, AIDS and, 51:347,356 Ammonium chloride, lysosomes and, 60: 284-285 Amphiregulin, transforming growth factor-a and, 58:28,37 Amphoterin, plasminogen binding, 69: 106 Amphotropic viruses development, from MuLV cancer resistant mice, 65: 177 effect of F v - 4 on, 65:190 Amplification, see Gene amplification Amplified DNA, evolution, 61:108-110 Amyloidosis, cutaneous lichen, with MEN IIA, 70:186-187 Anaphylaxis with desensitization reaction, Zilber and, 59:26-27 Anaplastic astrocytoma, oncogenesis of, 58: 124-125 8 Anatomy CpG islands in tumor suppressor genes, 72: 182-184 DNA methylation in higher-order eukaryotes, 72:147-150 Androgen receptor gene amplification in prostate cancer, 68: 247-248 mutations in prostate cancer metastasis, 68: 246 Androgens diet and, 51:63-64 endogenous growth inhibitors and, 57:436 mouse retrotransposons and, 56:231,240, 242 prostaticcancer and, 51:31-32 Anemia chromosome abnormalities and, 52:13 DHEA and, 51:418 protein tyrosine kinase GFRs and, 60: 52-53 refractory, see Refractory anemia Aneuploidy carcinogenesis and, role in cellular transformation, 65:2 1 chemical carcinogenesis and, 50:33 genomic instability and, 60:122,124, 135-136 p53 mutations and, 71:7-8 Angiogenesis in embryo chorioallantoic membrane, okadaic acid-induced, 61:164 FGF receptor multigene family and, 60: 2-3,35 fibroblast growth factors and, 59: 115-116,122,155 biological function, 59:140-142 tumors, 59:149,153-155 in human cancers, 67:266-267 and 1L-6 production, 66:ll inhibitors, 69:139-140,142 in vivo assays, 67:263-266 in Kaposi’s sarcoma, 53:83-84 normal cells, 69:135 occurrences, natural, 69:141 protein tyrosine kinase GFRs and, 6 0 5 0 regulation by VEGF-Flt receptors, 67: 28 1-282 role of SF, 67271-275 and scatter factor, 66:245 Subject Index separate from solid tumor development, 72: 18-19 therapeutic strategies using, 69160- 16 1 transforming growth factor-cu and, 58:47 tumor macrophage role, 6E269-270 PDGF role, 67:295-296 suppression, 67:309-310 tumor cells, 69:135-136,161-162 inducers, 69:142-149 inhibitor down-regulation, 69:149-156 mechanisms, 6 9 9 36- 137 phenotype, 69:139-141,156-159 subversion of normal physiological system, 69:141-142 Angiogenin, 69:144 Angioimmunoblastic lymphadenopathy, see Lymphadenopathy, angioimmunoblastic Angiolipoma, chromosomal aberrations, 69: 69-72 Angiopeptin, breast cancer therapy, 68:212 Angiostatin, 69:150,151 Angiotensin II,69:144 Animal models DNA methylation changes in cancer, 72: 175-1 76 lung carcinogenesis, p16 gene studies, 72: 162-163,187 Aniridia, Wilms’ tumor and, 59:47-50, 53-54,62 Ankyrin repeat domain, in IKB proteins, 66: 266-269 Antagonism, muscle cell regulation and, 58: 108-114 Antagonistic effects, cancer immunotherapy and, 59:262 Anthracyclins a-fetoprotein and, 56:280,287 lysosomes and, 60:284-285 multidrug resistance and, 52:170, 193 Antiandrogens, prostatic cancer and, 51:2 Antiangiogenic agents, 69160-161 Antibodies, see also Immunoglobulins; Monoclonal antibodies 4D5, HER-2/neu immunotherapy, 71:362 A .

Download PDF sample

Cumulative Subject Index Volumes 50-72 by George F. Vande Woude, George Klein


by Christopher
4.1

Rated 4.86 of 5 – based on 21 votes